PMID- 11412343
OWN - NLM
STAT- MEDLINE
DCOM- 20010726
LR  - 20190921
IS  - 0953-8194 (Print)
IS  - 0953-8194 (Linking)
VI  - 13
IP  - 6
DP  - 2001 Jun
TI  - The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in 
      vivo and in vitro in male rats.
PG  - 561-6
AB  - Orexin-A is synthesized in the posterolateral hypothalamus and immunoreactive 
      fibres project to many central nervous system structures, including the 
      paraventricular nucleus, which is rich in corticotropin releasing factor (CRF) 
      neurones and neuropeptide Y (NPY) innervation. We investigated the central 
      effects of orexin-A on the hypothalamic-pituitary-adrenal (HPA) axis by measuring 
      plasma concentrations of corticosterone and adrenocorticotropic hormone (ACTH) in 
      vivo. We explored the potential neuropeptide pathways involved by investigating 
      the effects of orexin-A on CRF, NPY, arginine vasopressin (AVP) and noradrenaline 
      release from hypothalamic explants in vitro. Intracerebroventricular (i.c.v.) 
      injection of orexin-A (3 nmol) in male rats stimulated increases in plasma 
      concentrations of corticosterone between 10 and 40 min after injection, and of 
      plasma ACTH at 20 and 90 min after injection. Orexin-A significantly stimulated 
      CRF and NPY release from hypothalamic explants in vitro. Orexin-A did not 
      stimulate CRF release in the presence of the selective NPY Y1 receptor 
      antagonist, BIBP3226. BIBP3226 alone did not alter CRF release from hypothalamic 
      explants. Orexin-A had no effect in vitro on the release of other neuropeptides, 
      AVP and noradrenaline, involved in the central regulation of the HPA axis. These 
      results suggest that orexin-A is involved in activation of the HPA axis, and that 
      these effects could be mediated via the release of NPY.
FAU - Russell, S H
AU  - Russell SH
AD  - ICSM Endocrine Unit, ICSM, Hammersmith Hospital, Du Cane Road, London W12 ONN, 
      UK.
FAU - Small, C J
AU  - Small CJ
FAU - Dakin, C L
AU  - Dakin CL
FAU - Abbott, C R
AU  - Abbott CR
FAU - Morgan, D G
AU  - Morgan DG
FAU - Ghatei, M A
AU  - Ghatei MA
FAU - Bloom, S R
AU  - Bloom SR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
RN  - 0 (BIBP 3226)
RN  - 0 (Carrier Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Neuropeptide Y)
RN  - 0 (Neuropeptides)
RN  - 0 (Orexins)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
RN  - 94ZLA3W45F (Arginine)
RN  - W980KJ009P (Corticosterone)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Adrenal Glands/*drug effects
MH  - Adrenocorticotropic Hormone/blood
MH  - Animals
MH  - Arginine/*analogs & derivatives/pharmacology
MH  - Arginine Vasopressin/metabolism
MH  - Carrier Proteins/administration & dosage/*pharmacology
MH  - Corticosterone/blood
MH  - Corticotropin-Releasing Hormone/metabolism
MH  - Culture Techniques
MH  - Hypothalamus/*drug effects/metabolism
MH  - Injections, Intraventricular
MH  - *Intracellular Signaling Peptides and Proteins
MH  - Kinetics
MH  - Male
MH  - Neuropeptide Y/metabolism
MH  - Neuropeptides/administration & dosage/*pharmacology
MH  - Norepinephrine/metabolism
MH  - Orexins
MH  - Pituitary Gland/*drug effects
MH  - Rats
MH  - Rats, Wistar
EDAT- 2001/06/20 10:00
MHDA- 2001/07/28 10:01
CRDT- 2001/06/20 10:00
PHST- 2001/06/20 10:00 [pubmed]
PHST- 2001/07/28 10:01 [medline]
PHST- 2001/06/20 10:00 [entrez]
AID - jne672 [pii]
AID - 10.1046/j.1365-2826.2001.00672.x [doi]
PST - ppublish
SO  - J Neuroendocrinol. 2001 Jun;13(6):561-6. doi: 10.1046/j.1365-2826.2001.00672.x.